You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中關村(000931.SZ):下屬公司北京華素簽署鹽酸哌甲酯緩釋咀嚼片項目技術轉讓(專利申請權)合同
格隆匯 02-28 15:45

格隆匯2月28日丨中關村(000931.SZ)公佈,公司於2024年2月28日召開第八屆董事會2024年度第二次臨時會議,審議通過《關於下屬公司北京華素簽署鹽酸哌甲酯緩釋咀嚼片項目技術轉讓(專利申請權)合同的議案》。

為進一步提升公司在麻精領域的競爭優勢,經過公司慎重研究、充分的可行性研究論證,公司全資子公司北京中關村四環醫藥開發有限責任公司之控股子公司北京華素製藥股份有限公司(以:北京華素)擬與中國融通科學研究院集團有限公司(簡稱:中國融通研究院)簽署《技術轉讓(專利申請權)合同》,公司擬以人民幣500萬元+上市10年銷售額3%(首筆不低於人民幣200萬元,此外每增加一個規格須額外支付50萬元)受讓取得中國人民解放軍軍事科學院軍事醫學研究院(以下簡稱:軍科院)鹽酸哌甲酯緩釋咀嚼片項目相關的專利申請權及技術資料(以下簡稱:交易標的)。本次交易事項採用里程碑式分期支付方式付款,軍科院收到款項後中國融通研究院協調辦理相關事宜。有關《技術轉讓(專利申請權)合同》尚未簽署。

本次交易標的為軍科院鹽酸哌甲酯緩釋咀嚼片項目相關的專利申請權及技術資料,標的項目現已完成小試研究工作,目前正開展中試準備工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account